NYSE
72.89USD
+1.56 (+2.19%)
We have scored 84 news catalysts on Zoetis Inc. (ZTS) over the past 12 months. The biggest single-day move next to one of them came May 10, 2026, when ZTS closed −5.1%: “Zoetis Q1 Review: Is A Darkened Outlook Cyclical Or Structural? (Rating Downgrade)”. Coverage across the window leans negative (average ticker sentiment −0.40). Most of the impact sits in price momentum and institutional appeal.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
30.6B
P/E
—
EPS
—
Beta
0.73
52W range
70.26-148.79
Day range
71.25–73.46
Open
71.98
Prev close
71.33
Volume
3.8M
Avg volume
6.5M
Dividend
2.09
IPO
2013-02-01
Analysts publish price targets on ZTS, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
12 analyst price targets from $80 to $115
as of 2026-08-27
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Zoetis Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for ZTS: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
The reconstruction
At $72.89, the stock sits at the very bottom of the published model range ($80 to $115), meaning the market entirely rejects the bull cases and assumes the competitive threats to the company's key brands are permanent, not temporary.
What the disagreement turns on
Is the market share loss in the U.S. companion animal dermatology and parasiticide franchises structural and permanent, or can the company arrest the decline through targeted price actions and promotional spending? The available data can measure this via quarterly segment revenue history, but cannot capture the specific prescription volume and dollar share data that would definitively settle the debate.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
Computed at $77.52 on 2026-08-27 — the quote has since moved -6%, so read this as a record of what was priced in then, not now.
